January 13, 2017
AbbVie’s eight-week ribavirin-free hepatitis C combination regimen of glecaprevir and pibrentasvir (G/P) has shown promise in genotype 1 Japanese patients without cirrhosis, according to the drug’s PIII study data. The US drug giant said on January 9 that 99% of...read more